Core Viewpoint - Meinuohua's subsidiary, Ningbo Meinuohua Tiankang Pharmaceutical Co., Ltd., is participating in the national organized procurement for drugs whose agreements have expired, with ten products expected to be selected for this procurement [1] Group 1: Procurement Participation - The company is involved in the bidding for the continuation of procurement for drugs that are part of the first to eighth batches of the national organized procurement agreements that have expired [1] - The expected selected products include Perindopril tert-butylamine tablets, Clopidogrel hydrogen sulfate tablets, and Empagliflozin tablets among others [1] Group 2: Procurement Timeline - The results of the procurement selection are anticipated to be implemented by the end of March 2026 [1] - The procurement cycle for the selected drugs will last from the actual execution date of the selection results until December 31, 2028 [1] Group 3: Procurement Prioritization - During the procurement cycle, medical institutions will prioritize the use of the drugs selected in this continuation procurement and ensure the completion of the agreed procurement volume [1]

Group 1 - The pharmaceutical and biotechnology industry is experiencing favorable policy developments, such as the National Healthcare Security Administration's release of the "Drug Communication Method (Trial)" and the joint issuance of the "Implementation Plan for High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)" by eight departments, which supports innovative pharmaceutical companies [1] - Enhua Pharmaceutical (002262), as a chemical pharmaceutical company, has a target price set at 32.00 yuan by institutions, with the latest price at 23.87 yuan, and a projected net profit growth of 21.63% year-on-year by 2026, indicating positive growth expectations [1] - Current institutional ratings for Enhua Pharmaceutical are neutral, but there is attention on the trend of profit improvement [1] Group 2 - Over the past week (February 6, 2026 - February 12, 2026), Enhua Pharmaceutical's stock price fluctuated within a range of 1.83%, with a maximum price of 24.10 yuan on February 12 and a minimum price of 23.20 yuan on February 6 [1] - On February 12, there was a net inflow of 4.8174 million yuan from major investors, and technical indicators show a fluctuating pattern, with a resistance level at 24.82 yuan and a support level at 22.76 yuan [1] - The pharmaceutical sector's return was 3.28%, outperforming the CSI 300 index, indicating a recovery in industry sentiment [1] Group 3 - On February 11, the financing purchase amount was 2.6204 million yuan, with a financing balance of 582 million yuan, reflecting active market liquidity [1] - There have been no significant announcements from the company recently, but industry policy dynamics may indirectly affect its valuation [1]

Group 1 - The core viewpoint of the news is that Xianju Pharmaceutical's subsidiary, Taizhou Xianju Pharmaceutical Co., Ltd., has been re-certified as a high-tech enterprise, allowing it to enjoy a 15% corporate income tax rate for three consecutive years from 2025 to 2027 [1] Group 2 - The company's project, "High-end Formulation Internationalization Construction Project," has been delayed from its original completion date of the end of 2025 to December 31, 2026. As of October 31, 2025, the project has invested 636 million yuan, achieving a progress rate of 90.79%. The delay is primarily due to the incomplete approval processes for certain products [2]

2026年2月5日，公司发布了2025年度以简易程序向特定对象发行股票的预案（二次修订稿），拟募集资 金1.59亿元用于陆芝葆化药生产车间与智能综合仓库项目建设。发行价格为8.45元/股，需经深圳证券交 易所审核及中国证监会注册后方可实施。 业绩经营情况 经济观察网 北陆药业（300016）发布定增预案，拟募资1.59亿元用于项目建设，同时公司预计2025年净 利润同比大幅增长537.28%至852.26%。此外，公司正积极拓展海外市场并推进产能扩建。 定增股票 2026年1月29日，公司预计2025年全年归属于上市公司股东的净利润为8700万元至1.3亿元，同比增长 537.28%至852.26%。正式年报尚未发布，最终数据以审计结果为准。 产能扩充 根据2026年1月22日的机构调研信息，公司正积极拓展海外市场，对比剂生产线已通过欧盟及巴西认 证，并推进海昌药业原料药产能扩建、沧州三期原料生产项目等，以支撑未来业务增长。 以上内容基于公开资料整理，不构成投资建议。 ...

Core Insights - The company has made significant progress in business expansion, product development, and market performance, particularly in the solid-state battery materials sector and lithium battery electrolyte additives [1] Business Development - The company has established a joint venture, Sichuan Luocheng New Materials Technology Co., Ltd., with Sichuan Saike Power to promote the research and industrialization of solid-state battery adhesives and other new energy materials, currently in small-scale or pilot testing [2] - The company is investing in a production capacity of 5,000 tons per year for lithium battery electrolyte additives, with the VC project in preparation for production [2] Product Development - The core product, injectable Labetalol Hydrochloride (including new specifications), successfully renewed its contract and was included in the national medical insurance directory as of December 2025 [3] - New drugs such as Aclidinium Bromide capsules and Sodium Thiosulfate injection were approved in 2025, indicating successful consistency evaluation [3] - The company has also applied for production approval for Acetate Cetrorelix injection, which is currently under review [3] Financial Performance - The company's Q3 2025 report shows revenue of 472 million yuan, a year-on-year increase of 30.80%, and a net profit of 32.68 million yuan, up 16.22% year-on-year, with growth in both revenue and net profit for the third quarter [4] Stock Performance - As of January 16, 2026, the company's stock price increased by 3.26% over the week, with a net inflow of 43.65 million yuan from major funds, indicating active trading [5] - The stock price experienced a limit-up on November 14, 2025, driven by solid-state battery concepts and performance catalysts, highlighting significant divergence between retail and institutional investors [5] Company Status - By the end of Q3 2025, new institutional investors, such as Zhongou Yuexiang Life Mixed Fund, entered the top ten circulating shareholders, reflecting increased investor interest [6] - The number of shareholders showed a slight concentration trend by the end of 2025 [6]

Core Viewpoint - The company is actively progressing with the registration review of its innovative drug, CXHS2400019, and is prepared for potential commercialization while addressing industry competition and operational pressures [1]. Group 1: Drug Approval and Commercialization - The registration review for the innovative drug, CXHS2400019, is currently in progress, with the specific timeline dependent on the National Medical Products Administration (NMPA) [1]. - The company maintains good communication with clinical institutions involved in the research, which lays a solid foundation for future commercialization efforts [1]. - The company is open to collaborating with experienced and capable teams for the promotion of the drug [1]. Group 2: Business Strategy and Financial Performance - The company is actively expanding its overseas sales and enhancing its Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) operations to reduce costs and improve efficiency [1]. - The company reported its first loss in 2025, indicating a challenging competitive environment in the pharmaceutical sector [1]. - The management is focused on maintaining shareholder interests and ensuring sustainable operations, with plans to dynamically adjust development strategies based on industry trends and actual business conditions [1].

Group 1 - The company has submitted an application for the issuance of overseas listed shares (H shares) to the Hong Kong Stock Exchange on February 11, 2026 [1] - The application materials for this issuance and listing have been published on the Hong Kong Stock Exchange website on the same day [1]

广济药业公告，控股股东长江产业投资集团有限公司承诺认购公司2026年向特定对象发行A股不超过 9493.67万股，不超过发行前总股本30%，发行价格不低于定价基准日前二十个交易日均价80%，认购资 金来源为自有及/或合法自筹资金；其所认购股份自发行结束日起36个月内不转让，因分配股票股利、 资本公积金转增股本等取得的股份同受限售。 ...

Core Viewpoint - Tianyu Co., Ltd. identifies non-sartan active pharmaceutical ingredients (APIs) such as sitagliptin and ezetimibe as core growth drivers, with expectations for continued rapid growth through 2026 and potential for further gross margin improvement due to economies of scale [1] Group 1 - Non-sartan APIs are expected to be a significant growth driver for the company [1] - The company anticipates maintaining rapid growth in the non-sartan API segment through 2026 [1] - There is potential for further improvement in gross margins as economies of scale become more pronounced [1]

Group 1: R&D and Client Collaboration - The company focuses on serving large multinational pharmaceutical companies and original research drug companies, aiming to provide raw materials for 8 original drug varieties and plans to add 1-2 new commercialized raw materials annually [2] - Established long-term strategic partnerships with renowned pharmaceutical companies such as Novartis and Sanofi, expanding collaboration from sartan raw materials to non-sartan raw materials, patent-expired drugs, and innovative drug projects [2] Group 2: CDMO Business Strategy - The company has built a solid service foundation and professional competitiveness in the generic drug raw material field, leveraging a comprehensive GMP system and compliance capabilities [3] - The CDMO business focuses on strategic clients, prioritizing high-potential projects during patent periods and late-stage development, ensuring significant scale benefits and customer loyalty [3] Group 3: Business Growth Outlook for 2026 - Raw material segment: Sartan raw materials' revenue share is expected to decline, while non-sartan raw materials (e.g., sitagliptin, ezetimibe) are projected to be core growth drivers, maintaining rapid growth and potential margin improvement [4] - CDMO business: Revenue may face pressure due to changing client demands, but the company is actively pursuing new project opportunities to maintain stability [4] - Formulation business: Expected to continue rapid growth due to expanding market channels, despite a small revenue base [4] - Acetonitrile project: The annual production capacity of 20,000 tons has passed acceptance in January 2026, targeting high-end fields such as peptides and small nucleic acids [4] Group 4: Profitability and Cost Management - Sartan raw materials maintain a gross margin above 30% despite competitive pricing pressures, with expectations for stable margins as prices stabilize [5] - Non-sartan raw materials' gross margin is expected to improve as production increases and costs decrease, aiming to align closer to sartan products [5] Group 5: R&D and Sales Expenses - The company's overall R&D investment will remain stable at approximately 2.5-2.8 billion annually, with a rising proportion allocated to raw materials and CDMO R&D [5] - Sales expenses are increasing rapidly in the formulation business due to its growth, with the company enhancing marketing control through digital systems [5]